|
Model | Types | Treatment time/ Dosage/Feeding regime | Disease | Beneficial effects | Mechanisms | Reference |
|
Animal | Nonobese GK rats | 10 weeks | Type 2 diabetes | MDA content ↓. Serum GPx activity ↓. Liver CAT activity ↓ | Activated NF-кB signaling pathway | [50] |
20 mg/kg/day |
Intragastrical injection |
Male SD rats | 48 hours | Ischemic reperfusion injury | NOx, MDA content ↓. SOD, GSH, CAT activity ↑ | Activated p38/MAPK | [51] |
10 mg/kg/day |
Intraperitoneal injection |
Male Wistar rats | 20 days | Periodontitis | iNOS expression ↓. OHdG expression ↑. NOx and nitrotyrosine formation ↓ | Activated the SIRT1/AMPK pathway | [52] |
10 mg/kg/day |
Oral gavage |
Male Wistar albino rats | 3 weeks | Rotenone-induced Parkinson | Striatal DA level ↑. CHOP, GRP78 mRNA expression ↓. Striatal caspase-3, xanthine oxidase activity ↓. Striatal IL-1β, PC levels ↓. Glutathione peroxidase activity ↑ | Activated Nrf2/antioxidant defense pathway | [53] |
200 mg/kg/day |
Oral gavage |
Male Wistar rats | 15 days | OHDA-induced Parkinson | TBARS, protein carbonyl levels ↓. Phospholipase A2 activity ↓. GPx, GR, CAT, and SOD activity ↑. COX-2 expression ↓ | Activated Nrf2 signaling pathway | [54] |
20 mg/kg/day |
Introgastric gavage |
C57BL/6 mice | 24 hours | Aging | Nox2 and Nox4 expression ↓. SOD1 and SOD2 expression ↑ | Activated AMPK and SIRT1 | [55] |
40 mg/kg/day |
Oral gavage |
Male ApoE-KO mice | 7 days | Cardiovascular diseases | SOD1, SOD2, SOD3, CAT, GPx1 mRNA expression ↑. Nox2 and Nox4 expression↓. 2-HE and ethidium ↓. MDA and 3-nitrotyrosine ↓. GCH1 mRNA expression ↑ | Activated SIRT1 | [56] |
30/100 mg/kg/day |
Oral gavage |
Male SAM | 5 days | Aging | SOD activity ↑. SOD mRNA expression ↑. Gpx activity ↑MDA level ↓ mtDNA deletion ↓ | | [57] |
25/50/100 mg/kg/day |
Introgastric gavage |
Adult male Wistar rats | 10weeks | Alcohol-induced cognitive deficits | Acetylcholinesterase activity ↓. Nitrite level ↓. Lipid peroxide ↓. GSH, SOD, CAT activity ↑. TNF-a, IL-1β, NF-kβ, caspase-3 levels ↓ | | [58] |
5/10/20 mg/kg/day |
Oral gavage |
Female Wistar rats | 16 weeks | Alcoholic liver disease | Liver AST, ALT levels ↓ CAT, GPx enzyme activity ↑. MDA level ↓. CYP2E1 protein expression ↓. Caspase 3 activity ↓SOD1, SOD2, SOD3, CAT, GPx mRNA expression ↑ | | [59] |
250 mg/kg/day |
Oral gavage |
Male Zucker rats | 6 weeks | Nonalcoholic fatty liver disease | MDA level ↓. GSH/GSSH ↑. SOD activity ↑. ACO, CPT-Ia activity ↑ | | [60] |
15/45 mg/kg/day |
Oral gavage |
Cell | HT22 cell | 12 hours | Glutamate-induced (2mM) Alzheimer and Parkinson | HO-1 expression ↑. The cytoprotective of HT22 cells ↓ | Activated SIRT1 signaling pathway | [61] |
2.5-10 μM |
Not given |
Oocytes | 12 hours | Doxorubicin-induced compromised fertility | ROS level ↓. CAT, Sod1, Gpx3 mRNA levels ↑. DNA damage ↓ | | [62] |
0.5/1/5 μM |
Not given |
Bronchial epithelial cell | 7 days | HDM-induced asthma | Cell apoptosis ↓. ROS level ↓ | Elevated the expression of SIRT1 | [63] |
100 mg/kg/days |
Intraperitoneal injection |
Metaphase II oocytes | 15 days | Postovulatory oocyte aging | ROS level ↓. MtDNA copy number ↓. Mitochondrial function ↑ | Coordinated SIRT1 and AMPK signaling pathways | [64] |
50 mg/kg/day |
Intraperitoneal injection |
Vascular smooth muscle cells | 24 hours | Age-related vascular disease | SM2-MHC protein expression ↑. Contractile capacity ↑ | | [65] |
0-100 μM |
Not given |
Neuroblastoma (N2a) cells | 48 hours | Alzheimer | Peroxiredoxins mRNA expression ↑. H2O2 level ↓. ATP level ↑. Lipid peroxidation production ↓ | Activated Nrf2 | [66] |
5 μM |
Not given |
Human bronchial epithelial cells | 24 hours | PQ-induced pulmonary fibrosis | Cell death, ROS production, mitochondrial damage ↓ TNFɑ, IL-6, TGFβ1 ↓ | | [67] |
10 μM |
Not given |
|